Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.60 |
| ▸ | LDHA | P00338 | 1/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.55 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | ATM | Q13315 | 1/20 | 0.54 |
| ▸ | KDM1A | O60341 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | ACACB | O00763 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.49 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.49 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30559576 | 1.00 | CA2 (0.60) | CA2LDHAALOX15ALOX12POLB | |
| SCHEMBL1023836 | 1.00 | CA2 (0.60) | CA2LDHAALOX15ALOX12POLB | |
| SCHEMBL1026086 | 1.00 | CA2 (0.60) | CA2LDHAALOX15ALOX12POLB | |
| Hydrochloric Acid SCHEMBL23524379 | 0.98 | CA2 (0.58) | CA2LDHAALOX15ALOX12POLB | |
| SCHEMBL15624585 | 0.85 | SIGMAR1 (0.46) | CA2LDHAALOX15ALOX12POLB | |
| SCHEMBL5277808 | 0.85 | ALOX15 (0.71) | ALOX15ALOX12MEN1KMT2A | |
| SCHEMBL3900627 | 0.85 | FOS (0.71) | ALOX15ALOX12ATMTAAR1 | |
| SCHEMBL4419063 | 0.85 | CYP2D6 (0.45) | CYP2D6SLC6A2SLC6A4SLC6A3TAAR1 | |
| SCHEMBL3900634 | 0.85 | FOS (0.71) | ALOX15ALOX12ATMTAAR1 | |
| SCHEMBL5277797 | 0.85 | ALOX15 (0.71) | ALOX15ALOX12MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250286048-A1 | SILICON-DOMINANT BATTERY ELECTRODES | ENEVATE CORP (US) | 2025-09-11 | — | — | US | claimed |
| CN-113924667-B | Silicon-dominant battery electrode | 新强能电池公司 | 2024-10-18 | — | — | CN | claimed |
| EP-3977545-A2 | SILICON-DOMINANT BATTERY ELECTRODES | Enevate Corporation (US) | 2022-04-06 | — | — | EP | claimed |
| CN-113924667-A | Silicon dominated battery electrodes | 新强能电池公司 | 2022-01-11 | — | — | CN | claimed |
| US-20200381711-A1 | SILICON-DOMINANT BATTERY ELECTRODES | ENEVATE CORPORATION | 2020-12-03 | — | — | US | claimed |
| EP-4079311-B1 | NMN AND DERIVATIVES FOR USE IN THE TREATMENT OF DEPRESSION AND/OR ANXIETY IN PATIENTS HAVING A FORM OF PARKINSONISM | NUVAMID SA (CH) | 2025-10-01 | — | — | EP | disclosed |
| US-20250286048-A1 | SILICON-DOMINANT BATTERY ELECTRODES | ENEVATE CORP (US) | 2025-09-11 | — | — | US | disclosed |
| US-20240417421-A1 | NMN And Derivatives For Its Use In The Treatment Of Depression And/Or Anxiety In Patients Having A Form Of Parkinsonism | NUVAMID SA (CH) | 2024-12-19 | — | — | US | disclosed |
| CN-119108538-A | Silicon-dominant battery electrode | 新强能电池公司 | 2024-12-10 | — | — | CN | disclosed |
| CN-113924667-B | Silicon-dominant battery electrode | 新强能电池公司 | 2024-10-18 | — | — | CN | disclosed |
| US-20240116971-A1 | NMN AND DERIVATIVES FOR ITS USE IN THE TREATMENT OF DEPRESSION AND/OR ANXIETY IN PATIENTS HAVING A FORM OF PARKINSONISM | NUVAMID SA (CH) | 2024-04-11 | — | — | US | disclosed |
| CN-117255689-A | NMN and derivatives for the treatment of depression and/or anxiety in patients suffering from one form of Parkinson's disease | 努瓦米德公司 | 2023-12-19 | — | — | CN | disclosed |
| US-5607953-A | ANTIISCHEMIC AGENTS | EISAI CO., LTD. (JP) | 1997-03-04 | — | — | US | disclosed |
| EP-0344577-B1 | Butenoic or propenoic acid derivatives | EISAI CO LTD (JP) | 1996-10-09 | — | — | EP | disclosed |
| US-5382595-A | Antiischemic agents | EISAI CO., LTD. (JP) | 1995-01-17 | — | — | US | disclosed |
| US-5177089-A | Antiischemic agent, vasodilator | EISAI CO., LTD. (JP) | 1993-01-05 | — | — | US | disclosed |
| US-5047417-A | Butenoic or propenoic acid derivatives | EISAI CO. LTD. (JP) | 1991-09-10 | — | — | US | disclosed |
| CN-1040366-A | Butenoic acid or acrylic acid derivative | EISAI CO LTD (JP) | 1990-03-14 | — | — | CN | disclosed |
| EP-0344577-A2 | Butenoic or propenoic acid derivatives | Eisai Co., Ltd. (JP) | 1989-12-06 | — | — | EP | disclosed |
| US-4490392-A | Benzylalcohol derivative and process for preparing | TANABE SEIYAKU CO., LTD. (JP) | 1984-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240116971-A1 | NMN AND DERIVATIVES FOR ITS USE IN THE TREATMENT OF DEPRESSION AND/OR ANXIETY IN PATIENTS HAVING A FORM OF PARKINSONISM | SNCA, NLN, PARK7 | CA2 4064/4885LDHA 247/4885ALOX15 4520/4885 |
| US-20240417421-A1 | NMN And Derivatives For Its Use In The Treatment Of Depression And/Or Anxiety In Patients Having A Form Of Parkinsonism | SNCA, NLN, PARK7 | CA2 4633/4885LDHA 507/4885ALOX15 2898/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.